App-Quantinova.ai

The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy.

Edward Pearson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Pre-cancer cardiovascular risk factors and anthracycline-related cardiotoxicity among non-Hodgkin lymphoma survivors.

Talya Salz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

N/A

Reproductive hormone levels modulate doxorubicin induced cardiomyopathy in female tumor-bearing spontaneously hypertensive rats

Kaytee L. Pokrzywinski - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Doxorubicin

Doxorubicin induced cardiomyopathy associated with natural reproductive hormone cycling in female tumor-bearing spontaneously hypertensive rats

Kaytee L. Pokrzywinski - American Association for Cancer Research (AACR) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

ADR-529

Cardiovascular diseases after Hodgkin lymphoma treatment: 35-year disease risk and sequence of events.

Frederika A. van Nimwegen - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Heart muscle disease

N/A

Cardiac outcomes in aging survivors of childhood cancer exposed to cardiotoxic therapy: A report from the St. Jude Lifetime (SJLIFE) Cohort Study.

Daniel A. Mulrooney - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

N/A

Risk factors for anthracycline-associated cardiotoxicity.

Raquel E. Reinbolt - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

N/A

Pulsed Radiofrequency Lesion of the Left Stellate Ganglion Provides Durable Suppression of Drug-Resistant Ventricular Arrhythmia

Jeffrey Chen - American Academy of Pain Medicine (AAPM) , 2015

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

Bupivacaine

Emergent Substitution of Fludarabine for Cyclophosphamide Due to Acute Cardiac Toxicity during Conditioning with Successful Engraftment

Hawazen Saleh Alsaedi - European Group for Blood and Marrow Transplantation (EBMT) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Heart muscle disease

Cyclophosphamide

Cardiovascular toxicity following anti-angiogenic therapy in persons over age 65 with advanced renal cell carcinoma.

Sekwon Jang - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Heart muscle disease

Sorafenib

The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.

Michaela Liedtke - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Heart muscle disease

NEOD001

Treatment-specific risks of second malignancy and cardiovascular disease in Hodgkin lymphoma survivors.

Simone de Vries - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Heart muscle disease

N/A

CELF4 variant and Anthracycline-related Cardiomyopathy (anth-card) A COG Study (ALTE03N1).

Xuexia Wang - American Society of Clinical Oncology (ASCO) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

N/A

Cardiovascular toxicity following aromatase inhibitor use in 13,273 survivors cared for in a HMO

Haque R - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Heart muscle disease

Tamoxifen

Chemical Chaperones Modulate the Development of Morphine Antinociceptive Tolerance

Tomohiko Aoe - American Society of Anesthesiologists (ASA) , 2014

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Heart muscle disease

Morphine

Hyaluronidase synthase 3 (HAS3) variant and anthracycline-related cardiomyopathy: A report from the Childrens Oncology Group.

Can-Lan Sun - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Hyaluronidase

The effects of dexrazoxane on cardiac status and second malignant neoplasms (SMN) in doxorubicin-treated patients with osteosarcoma (OS).

Lisa M. Kopp - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Heart muscle disease

Methotrexate

Intensive Monitoring of Cardiac Function and Extravascular Lung Water Predicts Outcome of Tako-tsubo Cardiomyopathy after Subarachnoid Hemorrhage

Tatsushi Mutoh - International Stroke Conference (ISC) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

SELECTIVE HOMOCYSTEINE LOWERING GENE TRANSFER ATTENUATES THE DEVELOPMENT OF PRESSURE OVERLOAD-INDUCED CARDIOMYOPATHY IN MICE

N. Singh - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

methionine

CORONARY ARTERY BYPASS GRAFTING IN PATIENTS WITH ISCHEMIA CARDIOMYOPATHY

CHUNG YI CHANG - European Atherosclerosis Society (EAS) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

Filters

3340 Abstracts